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Alzheimer’s disease (AD) is a major public health priority with a large socioeconomic burden and complex
etiology. The Alzheimer Disease Metabolomics Consortium (ADMC) and the Alzheimer Disease
Neuroimaging Initiative (ADNI) aim to gain new biological insights in the disease etiology. We report here
an untargeted lipidomics of serum specimens of 806 subjects within the ADNI1 cohort (188 AD, 392 mild
cognitive impairment and 226 cognitively normal subjects) along with 83 quality control samples. Lipids
were detected and measured using an ultra-high-performance liquid chromatography quadruple/time-of-
flight mass spectrometry (UHPLC-QTOF MS) instrument operated in both negative and positive
electrospray ionization modes. The dataset includes a total 513 unique lipid species out of which 341 are
known lipids. For over 95% of the detected lipids, a relative standard deviation of better than 20% was
achieved in the quality control samples, indicating high technical reproducibility. Association modeling of
this dataset and available clinical, metabolomics and drug-use data will provide novel insights into the AD
etiology. These datasets are available at the ADNI repository at http://adni.loni.usc.edu/
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Design Type(s) disease pathway analysis objective
Measurement Type(s) metabolite profiling
Technology Type(s) liquid chromatography-tandem mass spectrometry
Factor Type(s) diagnosis • age • biological sex
Sample Characteristic(s) Homo sapiens • blood
Background and Summary
In the past century, human life expectancy has improved considerably, but has also lead to an increased
in the number of patients of chronic diseases such as Alzheimer’s Disease (AD). AD is a
neurodegenerative disease that irreversibly destroys the normal ability of the brain to access memories
and make decisions1, and the affected person becomes demented with a decreasing quality of life.
The causes of the onset and progression of AD have not yet been identified but differ from normal
aging. While AD is associated with the presence of tau neurofibrillary tangles and amyloid beta (Aβ)
plaques in the post-mortem brain2–4, many other changes in both central and peripheral physiology have
been linked to the disease5. Previous research suggests that the disruption of lipid metabolism is part of
the pathophysiology of AD6. Lipids have clear roles in amyloidogenesis, neurotransmission, oxidative
stress, and apoptosis, all thought to be tied to AD progression. Both central and peripheral lipid
metabolism is altered in AD subjects and lipid metabolites in the cerebral spinal fluid and blood may
provide information on the metabolic pathways contributing to AD pathophysiology.
While tau and Aβ plaques are prominent among the recognized AD markers7,8, it is important to
identify other biochemical changes which are related to disease development and progression. By
identifying changes in other biological pathways associated with AD9, we suggest new targets to treat or
biomarkers to diagnose this disease. Our limited understanding of AD is one of the main reasons that we
cannot stop the progression of this disease10. Identification of biomarker and druggable target specific
genetic, molecular, and cellular mechanisms may help to prevent AD progression. However, results have
been unsatisfying to date11,12.
Progress in analytical chemistry now allows for the rapid and reproducible screen for hundreds of lipid
molecules from triacylglycerol, sphingomyelins, lysophosphatidylcholine, phosphatidylcholine, choles-
teryl esters, fatty acids and other lipid classes13, now referred to as lipidomics13–15. Lipidomics has been
frequently used to associate blood lipid changes with chronic diseases such as cardiovascular disease,
depression and AD6,16. Today, up to 800 different lipid molecules can be measured in human blood using
liquid chromatography-high resolution mass spectrometry17,18.
Lipids are a major chemical group that contributes significantly to the brain functioning19. A range of
studies suggest the role of hypometabolism in the progression of AD20–22. Diabetes and insulin resistance
also increase the risk of AD in older age23–28. Therefore, we hypothesized that the onset of AD may be
associated with body’s lipid metabolism. To test this hypothesis, blood lipid’s levels can be used to link
the lipid metabolism with AD. Previous studies support this hypothesis29–31, but evidence needs to be
validated and solidified for specific lipid classes. The link of blood lipids with onset and progression of
AD needs to be tested in large epidemiological studies so that the effect of confounding factors such as
aging, medication and gender can be taken into account while investigating the associations of AD with
lipids.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was initiated in 2004 to facilitate the
validation of biomarkers for clinical studies on AD32. ADNI32,33 provides a unified online platform to
researchers around the globe so that they can define the progression of Alzheimer’s disease. The platform
enables the collection, validation and use of data such as magnetic resonance imaging and positron
emission tomography images, genetics, cognitive tests, cerebral spinal fluid and blood biomarkers from
thousands of individuals as predictors for the disease34. A targeted metabolomics of ADNI1 cohort serum
specimens has been completed using the Biocrates AbsoluteIDQ p180 kit35. In the dataset, 121 lipids
species were measured using the flow-injection analysis-MS/MS and were reported using their semi-
quantitative intensities. The biocrates targeted method quantifies four lipid classes – acyl carnitines, lyso
phosphatidylcholine, phosphatidylcholines and sphingomyelins using the direction flow ionization mass
spectrometry. This analytical method suffers by the presence of isomeric lipid species in the sample
therefore one signal can represent several lipid species. Whereas a liquid chromatography (LC) based
separation can separate these isomeric lipid species and give multiple signals. In the presented data
descriptor, up to 13 lipid classes including triacylglycerols, ceramides, phosphoethanolamine, lysopho-
sphoethanolamine phosphoinositols, glyceroceramides, diacylglycerols, cholesterol esters were covered.
Several lipids in these classes are not covered by other biochemical datasets available at the ADNI
website35. For many lipids we have the acyl chain information available using their MS/MS spectra. For
this consortium, a comprehensive and untargeted lipidomics dataset is presented here for the study the
association body’s lipid metabolism with AD and its clinical features. The NIH-West Coast Metabolomics
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Center has developed a liquid chromatography and mass spectrometry based lipidomics assay of blood
specimens36–40. Here, we used a UHPLC-QTOF mass spectrometer to detect, identify and measure lipids
in blood samples from 806 individuals from the ADNI study and describe the details of the samples
preparation, data generation, quality controls, data filtering and normalization. The ADNI repository
hosts the whole genome sequencing, mitochondrial DNA sequencing, genotyping array, magnetic
resonance imaging, positron emission tomography scans, blood and cerebrospinal fluid protein and
peptide biomarker panel, medication use, anthropometric measurements, metabolomics and cognitive
measurements for the recruited participants. The primary use to the data descriptor is to discover
associations between serum lipid levels and these available information from the ADNI repository. To
find these associations, linear or logistic regression models need to be computed while adjusting for key
confounding variables such as age, gender or body mass index. Significant associations may indicate
which lipid metabolic pathways can be implicated in the AD etiology.
Methods
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort
The ADNI data repository (http://adni.loni.ucla.edu/) supplied all the demographic information,
neuropsychological and clinical assessment data, and diagnostic information used for this study and this
information has been published previously5. Prior Institutional Review Board approval was obtained at
each participating institution and written informed consent was obtained for all participants. Information
about ADNI can be found in Petersen et al. 2010 and at http://www.adni-info.org/.41 Key clinical and
demographic variables for the ADNI1 participants used in this study are summarized in Table 1 and are
available through Synapse (see Table 2). Note that ADNI data collection is ongoing, so variables on the
Laboratory of Neuro Imaging (LONI) repository may have been updated since the subset used in this
analysis was downloaded. Access to ADNI data can be requested at http://adni.loni.usc.edu/data-samples/
access-data/ after signing a data use agreement.
Serum specimen collection and sample management
Fasting blood samples from the baseline visit were included in the study (69 non-fasting samples were
excluded post analysis). Blood samples were collected in two bar-coded 10 mL red-top plastic Vacutainer
blood tubes, blood was allowed to clot for 30 min followed by a 15 min centrifugation at 3000 revolutions
per minute (1500 relative centrifugal force) as described in the ADNI standard operating procedures
(www.adni-info.org). The serum was transferred into a bar-coded 13 mL polypropylene transfer tube,
capped and frozen in dry ice. Samples were shipped overnight to the ADNI biomarker core laboratory at
the University of Pennsylvania Medical Center. In the core facility, samples were thawed and aliquoted to
0.5 mL samples, and then subsequently aliquoted once more for individual laboratory analyses. A 20 μL
sample aliquot was delivered for analysis with the lipidomics platform at the West Coast Metabolomics
Center at UC Davis. Samples were randomized before shipping to the analysis laboratories. As a positive
control, 20 samples replicated and inserted randomly across the analysis sequence.
Equipment and consumables for sample preparation and Liquid chromatography-mass
spectrometry (LC-MS) analysis
Equipment and consumables used for the sample preparation and the LC-MS data acquisition were -
Agilent 1290 Infinity UHPLC/6530 QTOF MS and Agilent 1290 Infinity UHPLC/6550 QTOF MS,
Acquity charged surface hybrid technology (CSH) C18 2.1 × 100 mm, 1.7 μm column (Waters, cat. no.
186005297) and Acquity VanGuard CSH C18 2.1 × 5 mm, 1.7 μm pre-column (Waters, cat. no.
186005303), centrifuge (5415D, Eppendorf), calibrated pipettes 10-200 μL and 100-1000 μL, Eppendorf
tubes (1.5 mL, uncolored, cat. no. 022363204), MiniVortexer (VWR), Orbital Mixing Chilling/Heating
Plate (Torrey Pines Scientific Instruments), speed vacuum concentration system (Labconco Centrivap)
with a cold trap, Agilent tune mix (Agilent, cat. no. G1969-85000), acetonitrile (ACN) (J.T. Baker, cat. no.
9829-03), formic acid (Fluka, cat. no. 94318-250mL-F), ammonium formate (Fluka, cat. no. 70221-25G-
CN (n = 226) MCI (n = 392) AD (n = 188) p-value
Age (years) 75.5 (72.2-78.4) 75.1 (70.1-80.4) 75.8 (70.8-80.5) 0.29
Gender (% Male) 47.8% 35.4% 47.6% 0.0019
APOE ε4 (%) 26.5% 53.3% 66.1% o0.0001
MMSE 29.0 (29.0-30.0) 27.0 (26.0-28.0) 23.0 (22.0-25.0) o0.0001
ADAS-Cog13 9.33 (6.0-12.3) 18.3 (14.7-23.0) 28.5 (23.7-34.0) o0.0001
Table 1. Baseline demographics and clinical data of studied ADNI subjects as determined at baseline.
APOE- Apolipoprotein E; MMSE- Mini–Mental State Examination; ADAS-Cog 13 Alzheimer’s Disease
Assessment Scale cognitive scale, 13-item version. P-values are based on Chi-square test for APOE status and
Kruskal-Wallace for all other variables. P-values were not corrected for multiple testing
www.nature.com/sdata/
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F), isopropanol (Sigma–Aldrich, cat. no. 34965-4 × 2.5 L), LC-MS grade water (Fisher, cat. no. W6-4),
methyl tert-butyl ether (MTBE) (Sigma–Aldrich, cat. no. 34875-100ML), methanol (Fisher, cat. no.
A456-4), toluene (Sigma–Aldrich, cat. no. 179418-500ML), ammonium acetate (Sigma–Aldrich, cat. no.
A7330-100G).
Internal standards
Cholesteryl ester (22:1) was purchased from Nu-Chek (cat. no. CH-848). Avanti Polar Lipids supplied the
pure standards for phosphatidylethanolamine (17:0/17:0) (cat. no. 830756 P), 1,2-diheptadecanoyl-sn-
glycero-3-phospho-(1’-rac-glycerol) (17:0/17:0) (cat. no. 830456 P), 1-heptadecanoyl-2-hydroxy-sn-
glycero-3-phosphocholine) (cat. no. 855676), C17 sphingosine (cat. no. 860640), C17 ceramide
(d18:1/17:0) (cat. no. 860517), sphingomyelin (d18:1/17:0) (cat. no. 860585), PC (12:0/13:0) (cat. no.
LM-1000), d7-cholesterol (cat. no. LM-4100), d5-triacylglycerol (17:0/17:1/17:0) (cat. no. 110544),
diacylglycerol (12:0/12:0/0:0) (cat. no. 110611), diacylglycerol (18:1/2:0/0:0) (cat. no. 800100),
monoacylglycerol (17:0/0:0/0:0) (cat. no. 110607) and phosphatidylethanolamine (17:1/0:0) (cat. no.
110699). d3-Palmitic acid (cat. no. D-1655) was supplied by CDN isotopes. For the extraction, methanol
containing a mixture of internal standards (without CE (22:1)) was prepared, while MTBE containing
cholesteryl ester (22:1) was used. These internal standards were used only for the retention time
recalibration. Signals across samples were corrected by a bioreclamation quality control plasma based
normalization method.
Extraction of lipids from the blood samples
Extraction solvents methanol (MeOH) and MTBE were sonicated for 5 min, then stored at -20 °C prior to
use. Serum and plasma (QC) samples were thawed at room temperature and placed on ice. Samples were
vortexed for about 5 s to obtain homogenized samples. For each sample, a 20 μL aliquot was transferred
to an Eppendorf tube and 225 μL of -20 °C cold MeOH containing a mixture of internal standards was
added. Samples were vortexed for 10 s. Then 750 μL of -20°C MTBE with CE (22:1) was added, vortexed
for 10 s and shaken for 6 min at 4 °C. LC-MS grade water (188 μL) was added and the mixture was
vortexed for 20 s. Samples were centrifuged for 2 min at 14,000 rcf. The upper organic phase was divided
into two aliquots of 350 μL. Solvents were removed under vacuum to complete dryness in a speed-
vacuum dryer. One aliquot was kept at -20 °C as backup, the other dried-down sample was re-suspended
in 100 μL of a MeOH/toluene (9:1, v/v) mixture containing an internal standard 12-[[(cyclohexylamino)
carbonyl]amino]-dodecanoic acid (CUDA) (Cayman Chemical, cat. no. 10007923) and vortexed for 15 s.
For quality controls and for normalizations, one blank negative control extraction was prepared per 10
actual samples from empty Eppendorf tubes as starting material, in addition to one Bioreclamation
plasma (BioreclamationIVT, cat. no. HMPLEDTA) QC sample per 10 actual study samples.
UPLC-QTOF MS analysis
Samples were analyzed in four batches. Before each batch, the ion source was cleaned and the VanGuard
pre-column was replaced. Extracts were separated using a charged surface hybrid (CSH) C18 column
(Waters). Data were acquired using a single charged surface hybrid 2.1 mm id × 100 mm length, 1.7 μm
particle C18 column (Waters). The mass spectrometer was tuned before each batch as per the vendor’s
instructions using Agilent tune mix (mass resolving power ~10,000 Full width at half maximum
(FWHM) and ~20,000 FWHM for the Agilent 6530 and 6550, respectively). A reference solution of
purine and HP-0921 (m/z 121.0509, m/z 922.0098 in electrospray ionization (ESI) ( + ) and m/z 119.0360
and m/z 980.0164 (acetate adducts) in ESI(–)) was used to correct small mass drifts during the
acquisition. Mobile phase A (60:40 ACN:water + 10 mM ammonium formate + 0.1% formic acid) was
prepared by mixing 600 mL ACN, 400 mL water, 1 mL formic acid and 630 mg of ammonium formate.
Mobile phase B solvent (90:10 IPA:ACN + 10mM ammonium formate + 0.1% formic acid) was prepared
by mixing 900 mL IPA, 100 mL acetonitrile, 1 mL formic acid, 630 mg ammonium formate previously
dissolved in 1 mL of H2O. Both solvents were mixed and sonicated for 10 min (twice) before their use.
For ESI(–) the composition of mobile phases was identical but 10 mM ammonium acetate (771 mg per
1 L) was used instead as modifier. Before starting each batch of sample analyses, one empty injection, five
solvent injections (MeOH/toluene 9:1 with CUDA internal standard), two extraction blanks and two
Bioreclamation pool plasma samples were injected. Instrument performance was monitored for column
ESI( + ) ESI(–)
Known Unknown Known Unknown
Target ions 423 92 252 205
Unique compounds 286 92 196 205
Internal standards 14 0 11 0
Table 2. Lipid ion database used the West Coast Metabolomics Center for generation of lipidomics
data matrices.
www.nature.com/sdata/
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backpressure and signal intensities of the reference compounds. The quadrupole/time-of-flight (QTOF)
mass spectrometers are operated with electrospray ionization (ESI) performing full scan in the mass
range m/z 65–1700 in positive (Agilent 6530, equipped with a JetStreamSource) and negative (Agilent
6550, equipped with a dual JetStream Source) modes producing both unique and complementary spectra.
Instrument parameters were as follows for the ESI ( + ) mode – gas temperature 325 °C, gas flow 8 l/min,
nebulizer 35 psig, sheath gas temperature 350 °C, sheath gas flow 11, capillary voltage 3500 V, nozzle
voltage 1000 V, fragmentor voltage 120 V and skimmer 65 V. In negative ion mode, gas temperature 200°
C, gas flow 14 l/min, fragmentor 175 V, with the other parameters identical to positive ion mode. Data are
collected in centroid mode at a rate of 2 scans per second. Injection volume was 1.7 μL for the positive
mode and 5 μL for the negative mode. The liquid chromatography gradient used a 0.6 mL/min linear
velocity flow rate. The gradient started at 15% B, ramped to 30% at 2 min, 48% at 2.5 min, 82% at 11 min,
99% at 11.5 min and kept at 99% B until 12 min before ramping down to 15% B at 12.1 min which was
kept isocratic until 15 min to equilibrate the column. The total run time was 15 min. Acquisition speed
was 2 spectra/s and the mass range was m/z 60-1700. After every ten cohort samples, one Bioreclamation
pooled plasma QC sample was analyzed. These samples were used for correction of the batch effect using
a local polynomial regression fitting (LOESS) polynomial regression based normalization approach. All
the acquired raw LC-MS data files are provided in the data record (ADNI1_LIPIDOMICS_RAW_DA-
TA_ESI_POS.zip (Data Citation 1) & ADNI1_LIPIDOMICS_RAW_DATA_ESI_NEG.zip) (Data
Citation 2) (see Table 2).
Raw LCMS data files were provided in the vendor format (.d) to avoid any data loss during the file
conversion. The format contains the information such as time-stamps of the data acquisition, instrument
parameters and the liquid chromatography gradient. These information are saved in readable xml files in
the vendor format (.d) directory. The format also has the back-pressure profile on the LC system which
can be helpful in checking the system stability. These vendor files can be converted to an open format
such as mzML using the Proteowizard MSConvert utility so they can be read into other software such as
mzMine. Because the conversion will ignore the key parameters such as the back-pressure profile, we
decided to provide the raw data in the vendor format.
Lipid ion database
A database of validated lipids that were routinely detected in blood samples has been compiled at the
West Coast Metabolomics Center over the past six years. In this database, annotated lipids are associated
with retention time, adducts, m/z value and InChiKeys, verified by accurate mass, isotope ratio, retention
time and MS/MS spectra matching to either commercial lipid standards or to the LipidBlast library42. In
the database, ESI positive mode had 515m/z values and ESI negative mode had 457m/z values. Table 3
summarizes the database content. The database had m/z values for 374 unique known lipids and 25
internal standards. A total 98 lipids had m/z values in both ESI(–) and ESI( + ) modes. Known unknown
lipids are species that have been observed consistently in blood samples from the metabolomics projects
at the West Coast Metabolomics Center at the University of California, Davis over last six years however
have not been annotated yet. They have only m/z values and retention time. The database is provided in
the data record (wcmc-lipidomics-database.zip).
LC-MS data processing
Using the ion database as a targeted list, we have extracted the ion chromatograms (EICs) for all the m/z
values using the Agilent MassHunter Qualitative Analysis (7.0) software. We have used a targeted signal
extraction strategy for the study. Find by formula (FBF) method in the Agilent Mass Hunter software was
used only for extracting ion chromatograms for the m/z values provided in the ion database. We have
extracted ion chromatograph for 1 min before and after the expected retention time for each m/z value.
Since the database already had adduct information, ‘no adduct’ parameter was chosen in FBF settings and
only m/z values were used. EICs were used later to obtain the peak height values for lipids. No peak
smoothing and integration method was applied to the EICs. The ion database had retention time
information that exactly where the peak maxima for a lipid m/z value is so we have extracted peak
maxima for each peak at the corresponding retention time. For example TG (58:8) [M + NH4]
+ has m/z
value 948.8015 and expected retention time 10.167 min in the ion database. We first extracted the ion
profile in the range 10.06-10.26 min and then obtained the max value of that profile as peak maxima for
TG (58:8) [M + NH4]
+. All the EICs are provided at the LONI database. Using the Agilent DA
Reprocessor offline utility tool, the method was applied to all the raw LCMS data files (.d) in a batch
mode. Data processing method files are provided in the data record (adni1-qual-method.zip). The output
CSV files are provided in the data record (adni1-lipidomics-eics.zip) in Data Citation 3. These files
contain intensities of the ions over the retention time range (retention time ± 1.0 min) for each m/z value
from the target database. These CSV files were imported into R software for further data processing. First
the retention time of the internal standard were obtained for each sample. A retention time window of
0.2 min was used for finding the peaks for internal standards. Observed retention times for the internal
standards were determined by finding the time point at which the intensity of the m/z value was
maximum within the retention time range. A polynomial regression of second order (quadratic) curve
was fitted between the expected and observed retention times of the internal standards. The retention
times of the remaining compounds in the target database were recalibrated using the regression model.
www.nature.com/sdata/
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The updated retention times were used with a window of 0.20 min for each metabolite to extract the m/z
intensities values belonging to that ion from the CSV files. Maximum intensity values within the retention
time window were used as the peak height of the target compounds. Extracted targeted peaks for each
sample were exported as .txt files. These files were imported into R and merged to form the raw
lipidomics dataset. The signal-to-noise ratio was calculated by dividing the detected peak height of a lipid
by the median of ion intensities within the retention time range for the m/z value of that lipid. Next, data
were first normalized using the LOESS algorithm to remove trends and drifts in the data set within each
batch for each individual lipid. Then, a median normalization was applied across all the batches. In order
to prevent overfitting, the degree of smoothing for each LOESS curve was determined using leave-one-out
cross validation. We used a 5-fold cross validated relative standard deviation (RSD) of the QC samples to
measure the performance of the normalization procedure. The scatter plots of the injection order and the
signal intensity for individual lipids and the principal component analysis plots of the overall dataset
before and after the LOESS correction are provided in the data record(“adni1_loess_results.zip”)
Raw LC-MS data were acquired in an untargeted fashion and have been made available through
LONI’s data repository. A targeted signal extraction strategy was used to generate the lipidomics data
matrix. First, ion profiles for all m/z values, 515 in ESI( + ) mode and 457 in ESI(–) mode were extracted
from the raw LC-MS data files. For several lipids, more than two ions representing multiple adducts were
extracted in both ESI positive and negative modes. Then a data filtering pipeline was used to select one
adduct for each lipid with the lowest technical variance in the quality control samples. For example, if
lipid X has two adducts (a1 + , a2 + ) in ESI( + ) and two (a1-, a2-) in ESI(–) modes. First, one adduct in
each mode was selected using the lowest QC RSD criteria. For example, a1 + and a2- were selected. Then
it was determined which one of these two has lowest RSD in QC samples and that was included into the
final data matrix and the data dictionary. And if lipid Y has one adduct (a1 + ) in ESI( + ) and one (a1-) in
ESI(–) modes. For this, it was determined which one of these two has lowest RSD in QC samples. Peak
heights of those selected ions were used as a measurement for lipid species in one ionization mode. After
filtering out multiple adducts for the same lipid, a total 367 entries in ESI ( + ) and 280 entries in ESI (− )
modes files were remained. A total 98 lipids were detected in both modes. To minimize the penalty for
File Name Description Type Location URL
Primary Files
ADMC_ADNI1_LIPIDOMICS.csv Normalized & filtered lipidomics dataset. First column in this file is the
RID and rest of the columns are lipid ids.
Data LONI http://dx.doi.org/10.7303/syn10208594.1
ADNI_ADMCLIPIDOMICS_DICT.csv Data dictionary for lipid species. It has the ionization mode, adduct
information, precursor ion value, retention time and InChiKey values.
Data Dict LONI http://dx.doi.org/10.7303/syn10208614.1
ADMC Supplemental Materials
ADNI1_LIPIDOMICS_RAW_DATA_ESI_POS.zip Raw LC-MS data files (ESI + mode) in the Agilent (.d) format. Data LONI http://dx.doi.org/10.7303/syn10495782.1
ADNI1_LIPIDOMICS_RAW_DATA_ESI_NEG.zip Raw LC-MS data files (ESI -mode) in the Agilent (.d) format. Data LONI http://dx.doi.org/10.7303/syn10495771.1
wcmc-lipidomics-database.zip Curated database of plasma lipid ions for ESI ( + /-) modes. It has m/z
values, adduct information and retention time for the targets.
Metadata Synapse http://dx.doi.org/10.7303/syn10208660.1
adni1-lipidomics-acq.zip Agilent Qual 7.0 method that used for the data acquisition on the LCMS
instrument.
Method Synapse http://dx.doi.org/10.7303/syn10208671.1
adni1-lipidomics-eics.zip Extracted Ion Chromatograms in .csv format for ESI ( + /-) modes. These
files were generated by the Agilent Qual software.
Data LONI http://dx.doi.org/10.7303/syn10495758.2
adni1-lipidomics-script.r R-script for data generation and quality control Script Synapse http://dx.doi.org/10.7303/syn10208679.1
adni1_acqtime.zip Details about sample acquisition time and labels. It is required by the
R-script
Method Synapse http://dx.doi.org/10.7303/syn10208662.1
adni1_qcrsd_ttest.csv RSDs in QC samples and the p-values (student t-test paired) for duplicates
samples
Data LONI http://dx.doi.org/10.7303/syn10208665.3
adni1_lipidomics_data_processing.zip Input, intermediate and output data matrices used by the R-script. Data Synapse https://www.synapse.org/#!Synapse:
syn12973205
adni1_lipidomics_isa_tab.zip ISA-tab file for the RID to raw LCMC data files mapping Data Synapse https://www.synapse.org/#!Synapse:
syn12972536
adni1_loess_results.zip PCA plots for before and after the LOESS normalization Data Synapse https://www.synapse.org/#!Synapse:
syn12973204
Clinical Data
ADNI_All_Clinical_Data_16May2016.csv Clinical variables (a subset of ADNI’s complete list) snapshot from May,
2016
Data LONI http://dx.doi.org/10.7303/syn7477271.1
Fasting Status.txt Fasting status of participants at time of blood draw Data Synapse http://dx.doi.org/10.7303/syn9774830.1
ADNI Key Clinical Variables Subset Data Dictionary.
xlsx
Data dictionary for a key subset of variables in
ADNI_All_Clinical_Data_16May2016.csv (for full version see “Data
Dictionary [ADNI1,GO,2] (DATADIC.csv)” on LONI)
Data dict Synapse http://dx.doi.org/10.7303/syn9758900.1
Table 3. Description of data records.
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multiple hypothesis testing while calculating false discovery rates for regression modelling, duplicate
entries for lipids were removed by using the relative standard deviation in the quality control samples. An
entry with lowest RSD should be selected for lipids having duplicate entries in the dataset. We have also
computed the spearman correlation between peak heights values in both modes for lipids. Out of the total
98 duplicate detection in both mode, 80 (81%) showed a correlation of 0.80 or more, indicating that the
pairs belong to same lipid species and have good quality data in both modes. The lower correlation for
rest of 12 pairs can be attributed to poor detection in one ionization mode or presence of isomers.
Therefore, we have used the RSD in QC samples for all these pairs to decide which lipid should be
included in the data matrix that is ready for statistical analysis. Final data matrix had 513 unique lipids
species out of which 341 were known lipids and 172 were known unknowns. This final dataset is provided
in the data record (ADMC_ADNI1_LIPIDOMICS.csv) in Data Citation 4. Details about the measured
lipid species are provided in the data record (ADNI_ADMCLIPIDOMICS_DICT.csv). Raw input
matrices for ESI (− ) and ESI ( + ) modes and intermediate matrices during the data filtering and merging
steps have been provided in the data record (data_processing_matrices.zip). The R-script file describes
the steps at which these files were generated during the data processing.
Untargeted lipidomics assays allow a broad survey of lipid classes and changes in their levels. In these
assays, lipid’s chromatography peak height or integrated peak area represents its levels in a sample38,43,44.
As pure chemical standards for every detected lipids species in an untargeted assay are not commercially
available, it is not feasible to precisely estimate the absolute molar concentrations of them, therefore, peak
heights are used for creating lipidomics data matrices. Statistical analyses of those peak heights across
study samples identifies the significant lipid species that associate with an outcome of interest45. Use of
the QC based LOESS normalization method removed the batch effect in this study so that samples can be
compared for statistical purposes within the study. So if a compound has a mean peak height of 25,000 in
a disease group and a mean peak height of 75,000 in a control group, these values can reliably be used to
determine a 3 fold decrease in levels of the compound in the disease group in comparison to the control
group. Since internal standard for every measured lipids are not available, it is not possible to precisely
assess the signal linearity or concentration ranges for every lipid. Nevertheless, the Agilent 6530 and 6550
UHPLC-QTOF instruments that were used in the study have a linear dynamic range of up to 3 orders of
magnitude. This range can provide reliable signals to identify up to a 100 fold decrease or increase in the
levels of a majority of lipids, for example a mean peak height of 25,000 in cases versus 2,500,000 in
control samples. Peak height of one compound can only be used to compare its level across samples, it
cannot be compared with another compound’s peak height due to different ionization efficiency. For
example, if lipid A has a peak height of 25,000 and lipid B has 50,000, this does not mean that lipid B is
two times more than lipid A. It is needed that the data matrix need to be scaled and transformed
according to the statistical analyses.
Reversed-phase LC column with C18 sorbent and gradient separate lipid species by lipophilicity, thus, it
can separate two chemically different lipids even with same mass. However it cannot separate two lipids
species having same lipophilicity and mass values. In this case MS/MS spectra collected for particular peak
can inform if the peak consists of one or more co-eluting compounds. For example, there can be multiple
isobaric lipid species under one chromatographic peak, for example TG (48:0) may consist of TG
(16:0/16:0/16:0), TG (18:0/16:0/14:0), TG(18:0/14:0/16:0) and TG(14:0/18:0/16:0), depending on the acyl
chains. These isomers may elute at the same time and thus provide just a single peak. To confirm the purity
of such peaks, MS/MS spectra were collected for each lipid species and we have confirmed that up to 70% of
the peaks have only one lipid species as per matching their MS/MS spectra against LipidBlast library. NIST
MS Search software was used to search the MS/MS spectra against LipidBlast library and then each spectrum
was manually checked. TG (48:0) has a clean MS/MS spectrum and we have confirmed that it is TG
(16:0/16:0/16:0). Rest 30% of the peaks showed mix MS/MS spectra with multiple isobaric lipid possibilities,
and for them we have selected the most abundant acyl chains in the MS/MS spectra as acyl chain annotation.
Because acyl chain’s sn position could not be determined for several lipids, the naming convention uses “_”
instead of “/” for the lipids with multiple acyl chains in the lipidomics dataset.
Statistical analysis
Principal component analysis, paired t-test, histogram and calculations of relative standards deviations
were performed in the R programming language version 3.4.0.
Code availability
R script to generate the lipidomics dataset from the extracted ion chromatograms is provided in data
record (adni1-lipidomics-script.r).
Data records
The primary access site for this dataset is through Sage Bionetworks’ Synapse platform: https://www.
synapse.org/#!Synapse:syn9993525. Detailed information about ADMC data are provided in https://www.
synapse.org/#!Synapse:syn5592519. Input raw LC-MS mass spectra data files (Fig. 1) are found in (Data
Citation 1) and (Data Citation 2) for ESI positive and negative mode respectively. Extracted ion
chromatograms (Fig. 1) are available at (Data Citation 3). Processed data matrix for association modeling
is available at (Data Citation 4). ADNI’s data use agreement prohibits redistribution of ADNI data
www.nature.com/sdata/
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outside of LONI, so actual data files are hosted by the University of Southern California’s Laboratory of
Neuroimaging (LONI). The scripts used for data processing and medication mapping, however, reside in
the Synapse platform. Core data files along with associated metadata files, scripts, and supplemental files
are listed in Table 2. Note that ADNI requires registration to access the raw LCMS data files and
processed data matrices. Researchers may apply for data access at https://ida.loni.usc.edu/collaboration/
access/appLicense.jsp.
Technical validation
For the technical verification of the lipidomics dataset workflow, we analyzed the quantities of internal
standards and measured lipids in study samples, duplicate samples and quality control samples. First, we
performed a principal component analysis (PCA) of the lipidomics dataset to test for overall lipid and
sample variance, for example, to screen for outliers. The PCA score plot showed a larger-variance cluster
of human cohort samples and a small-variance cluster of Bioreclamation QC samples (Fig. 2). Of the total
variance, 95% was explained by the difference between these two clusters in principal component 1,
compared to only 1.2% variance by the next-most important vector, principal component 2. Analysis of
sample groups by further principal components did not reveal any impact of batch effects or injection
time points, showing that this data set does not contain major injection bias error or other hidden bias
groups.
To calculate the quality of the dataset generated by the lipidomics workflow, we computed the relative
standard deviations of the intensity levels of the internal standards, as these were not used in the
normalization scheme. Fig. 3 shows these values for positive and negative electrospray ionization modes
before and after LOESS normalization. All internal standards showed reproducibility better than 20%
RSD, proving that the data acquisition and data processing method has produced a high-quality
lipidomics dataset.
To show the technical reproducibility of the lipidomics assay, we have accessed the RSDs of measured
lipids in the QC samples. Levels of high quality lipids should not change much in quality control samples,
providing evidence our data processing methods are robust and reproducible. Fig. 4 shows the histogram
of these RSDs. In the same manner as the internal standards (Fig. 3), we see that more than 95% of all
Figure 1. Overview of the lipidomics data generation workflow.
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lipid species were detected at a reproducibility of better than 20% in the QC samples, highlighting the
excellent quality of the data. Consequently, we removed lipids from the data set that showed technical
errors of more than 25% RSD. Finally, a paired t-test analysis of the replicated samples (n = 20) shows
that up to 80% of the lipid species were not significantly different (p> 0.05), showing the removal of the
batch effect by the data processing pipeline and the low analytical variability in this dataset. Results of
RSD in QC samples and p-values of paired t-test in duplicate samples are provided in the data record
(adni1_qcrsd_ttest.csv).
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As demonstrated for Fig. 5, we detected no discernible carry-over effect when overlaying blank and
sample total ion chromatograms. The same quality was found when investigating the data for extracted
ion chromatograms, including triacylglycerides or cholesteryl esters.
Usage Notes
Investigators using the ADNI metabolomics data are subject to the general ADNI data usage access
policies and user agreements. Details on how to apply for access, and usage rules can be found at the
ADNI website: http://adni.loni.usc.edu/data-samples/access-data/. ADNI is one the largest cohort studies
on Alzheimer’s disease. It is funded by National Institute Aging as one of their flagship studies with a
mandate that all the acquired datasets will be made publicly available without a wait for a formal
publication. It is the only human cohort study that has provided genetics, imaging, clinical, medical,
pathological and biomarkers datasets in a single repository and have made it publicly available, enabling
combined analysis of these heterogenous datasets. It has ensured the use of single subject identifier across
all datasets, enabling a seamless data merging. All the data have been submitted to ADNI repository with
a quality control report and a data dictionary so new users can understand the measured variables
without contacting the original data submitters. ADNI study sets an unprecedented example for how
large human cohorts studies with heterogenous datasets can be catalogued and publicly shared to enable
new analyses that goes beyond one research group. Because ADNI is a human cohort study with available
genetics and other medical datasets, a new user need to first register and agreed to the term of fair use of
data and the code of conduct. There are no repository including metabolomics workbench or
metabolights that can accept these other datasets such as whole genome sequencing data, MRI-scans,
blood proteomics and medication data for a human cohort study. Therefore, we have decided to submit
the raw LCMS data files and all the processed results into ADNI and Sage Bionetwork repositories.
Several additional files were generated for the lipidomics assay which could not be submitted to the ADNI
repository, we have provided them at the Sage Bionetwork repository for new users. To confirm with the
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Figure 4. Reproducibility of peak heights for the detected compounds in QC samples. Histogram shows
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0 5 10
retention time (mins)
P
ea
k 
in
te
ns
ity
(io
n 
co
un
ts
 p
er
 s
pe
ct
ra
)
Blanks
QCs
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ADNI’s data usage terms, a new user also need to register at the Synapse website to access these files.
First, a new user need to register at the http://adni.loni.usc.edu/data-samples/access-data/ to get access to
the ADNI data. Then a user need to register at the Synpase.org to get access to the additional files at the
project page at https://www.synapse.org/#!Synapse:syn9993525. To access the ADNI data user need to go
to the https://ida.loni.usc.edu/pages/access/studyData.jsp. The page lists genetics, imaging, clinical and
biomarkers datasets for the ADNI study. Because both databases are managed by different entities, users
must register for separate user accounts for ADNI and Synapse respectively.
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